KyungDong Pharm home
Prescription Medicines

Lipigrel Tab. 100mg

Product Category
Cardiovascular Medicines
Active Ingredients
Sarpogrelate hydrochloride
Appearance
A white, round, film-coated tablet.
Reimbursement Code
653805440
View Regulatory Information on the MFDS Portal ↗
1. Ingredient content
1 tablet
- Active ingredient: Sarpogrelate hydrochloride (KP) ----- 100mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Magnesium stearate, citric acid hydrate, Opadry White (OY-C-7000A), sodium starch glycolate, calcium carboxymethyl cellulose, colloidal silicon oxide, Prosolv, hydroxypropyl cellulose

2. Effectiveness
Improvement of ischemic symptoms such as ulcers, pain, and cold sensation caused by chronic arterial occlusion (Buerger's disease, obstructive arteriosclerosis, diabetic peripheral angiopathy, etc.)

3. Dosage and dosage
Adults: As sarpogrelate hydrochloride, take 100 mg orally three times a day after meals.
Increase or decrease appropriately depending on symptoms.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with bleeding (hemophilia, capillary weakness, digestive tract ulcer, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.) (may increase bleeding).
2) Pregnant women or women who may be pregnant (refer to the section on administration to pregnant women and lactating women)
3) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Administer with caution to the following patients.
1) Patients during menstruation (there is a risk of increased bleeding)
2) Patients with bleeding tendency or such predisposition (there is a risk of intensifying the bleeding tendency)
3) Patients taking anticoagulants (warfarin, etc.) or drugs that inhibit platelet aggregation (aspirin, ticlopidine, cilostazol, etc.) (there is a risk of increased bleeding tendency).
4) Patients with severe renal impairment (there is concern that excretion may be affected)
5) Elderly people

3. Adverse reactions
The frequency of adverse reactions was sometimes classified as 0.1% or more to less than 5%, and rarely less than 0.1%.
1) Serious adverse reactions
(1) Bleeding tendency: Occasionally, bleeding such as gastrointestinal bleeding (e.g., hematemesis, bleeding, etc.), cerebral hemorrhage, and subcutaneous hemorrhage may occur, so observe thoroughly and take appropriate measures, such as discontinuing administration, if such symptoms appear.
(2) Blood disorders: Agranulocytosis, sometimes anemia, rarely platelet reduction, white blood cell reduction, etc. may occur, so observe thoroughly, and if adverse reactions occur, discontinue administration and take appropriate measures.
(3) Acute hepatitis, liver failure, or jaundice: Occasionally, liver dysfunction and jaundice accompanied by elevations of bilirubin, AST, ALT, ALP, γ-GTP, and LDH may occur, so observe thoroughly and take appropriate measures, such as discontinuing administration if these symptoms appear.
2) Other adverse reactions
(1) Hypersensitivity reaction: Erythema, urticaria, sometimes rash, redness, and rarely papules and itching may occur. If these symptoms appear, discontinue administration.
(2) Digestive system: Vomiting, stomatitis, sometimes nausea, foreign body sensation (esophagus), heartburn, abdominal pain, constipation, and rarely, loss of appetite, abdominal bloating, and diarrhea may occur.
(3) Circulatory system: Occasionally, palpitations, shortness of breath, chest pain, facial flushing, and swelling of the hands may occur.
(4) Mental nervous system: Drowsiness, loss of taste, headache, and rarely dizziness may occur.
(5) Kidney: Sometimes proteinuria, urinary occult blood, elevated BUN, and elevated creatinine may occur.
(6) Others: pharyngeal pain, pharyngeal discomfort, pharyngeal burning, sometimes weight gain, increased serum triglycerides, increased serum cholesterol, decreased serum albumin, decreased serum calcium, urinary sugar, urinary sediment, rarely edema, malaise, paralysis, fever, fatigue, etc. may occur.
3) As a result of a post-marketing survey conducted on 626 people over 6 years for re-examination in Korea, heartburn, diarrhea, headache, digestive tract bleeding, epistaxis, increased AST and ALT, increased bilirubin, increased cholesterol, and increased triglyceride were reported in 11 cases.

4. Generalism
It is advisable to have regular blood tests while taking this medicine.

5. Interaction
Caution should be exercised when coadministered with anticoagulants (warfarin, etc.) or drugs that inhibit platelet aggregation (aspirin, ticlopidine, cilostazol) as it may promote bleeding.

6. Administration to pregnant and lactating women
1) In animal experiments (rats), increased fetal mortality and decreased neonatal survival rates have been reported, so do not administer to pregnant women or women who may be pregnant.
2) Since secretion into milk was reported in animal experiments (rats), it is recommended not to administer to lactating women, but if administration is unavoidable, avoid breastfeeding.

7. Administration to children
Safety for children has not been established (there is no experience with use).

8. Administration to elderly people
In general, elderly people often have reduced physiological functions of the kidneys and liver, so there is a risk that high blood levels may persist. Therefore, administration should be done carefully by observing the patient's condition, such as starting administration at a low dose (e.g., 150 mg/day).

9. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

10. Pharmaceutical equivalence test information
A. The test drug Anthrom tablets 100 mg (sarpogrelate hydrochloride) (Pamgen Science Co., Ltd.) and the control drug Anplag tablets 100 mg (sarpogrelate hydrochloride) (Yuhan Corporation) were administered orally once on an empty stomach to healthy adults in a 2 When Cmax) was log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference for AUCt was within log0.8 to log1.25, and the 90% confidence interval of the mean difference for Cmax was outside log0.8 to log1.25. However, since the average difference in Cmax is within log 0.9 to log 1.1, and the submitted comparative dissolution test data are equivalent, it has been proven to be biologically equivalent in accordance with the proviso to Article 17, Paragraph 3 of the Pharmaceutical Equivalence Test Standards.
※ Table: Refer to attached document
※ This drug uses the same raw materials as Pamgen Science Co., Ltd. Anthrom Tablet 100mg (sarpogrelate hydrochloride) and the entire process was manufactured by Pamgen Science Co., Ltd. using the same manufacturing method.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 100 tablets/bottle

7. Period of use
36 months from date of manufacture